The fundraise announced Tuesday comes alongside news that Vaderis has started late-stage testing of that experimental drug, called engasertib, in people with hereditary hemorrhagic telangiectasia, or HHT. The company now has enough cash to sell engasertib on its own should the drug succeed in testing and get to market. It also results in the appearance of small, visible blood vessels on the skin called telangiectasias. Multiple types of cancer drugs, among them Roche’s Avastin, are also used off-label to treat complications. With engasertib, Vaderis is taking a page from those cancer drugs, but specifically tailoring its treatment to HHT patients.